Heron Therapeutics Inc (OQ:HRTX)

Business Focus: Biotechnology & Medical Research

Jun 25, 2019 07:20 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc. (“Heron” or “the Company”) (NASDAQ: HRTX) for violations of §§10(b) and 20(a) of the Securities...
Jun 22, 2019 06:15 am ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM: Announces Filing of Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive (the...
Jun 21, 2019 12:11 pm ET
Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit...
Jun 21, 2019 11:00 am ET
Intersect ENT, Inc. (XENT), Community Health Systems, Inc. (CYH) & Heron Therapeutics, Inc. (HRTX) - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 19, 2019 05:37 am ET
SHAREHOLDER ALERT: PSMT INVVY MOMO HRTX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jun 18, 2019 05:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Indivior, Heron Therapeutics, Mammoth Energy, and ChinaCache and Encourages Investors to Contact the Fi
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Indivior, Heron Therapeutics, Mammoth Energy, and ChinaCache. Stockholders have until the deadlines listed below to petition...
Jun 18, 2019 04:00 pm ET
TOP RANKED ROSEN LAW FIRM: Announces Filing of Securities Class Action Lawsuit Against Heron Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – HRTX
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive (the...
Jun 18, 2019 12:48 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Heron Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – HRTX
Pomerantz LLP announces that a class action lawsuit has been filed against Heron Therapeutics, Inc. (“Heron” or the “Company”) (NASDAQ:  HRTX) and certain of its officers.  The class action, filed in United States District Court, for the Southern...
Jun 18, 2019 10:47 am ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Heron Therapeutics, Inc. (“Heron”) or the (“Company”) (NASDAQ:HRTX) of the August 5, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Jun 18, 2019 08:59 am ET
HRTX Class Action Deadline: Bernstein Liebhard LLP Reminds Investors That Approximately 7 Weeks Remain to Make a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Heron Therapeuti
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announced that approximately seven weeks remain to make a motion to serve as lead plaintiff in a class action pending against Heron Therapeutics, Inc. (“Heron,” “HRTX” or the...
Jun 18, 2019 07:00 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc. (“Heron” or “the Company”) (NASDAQ: HRTX) for violations of §§10(b) and 20(a) of the Securities...
Jun 17, 2019 04:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Heron Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - HRTX
NEW YORK, June 17, 2019 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Heron Therapeutics, Inc. ("Heron" or the "Company") (NASDAQ: HRTX) and certain of its officers.  The class action, filed in United States District Court, for the Southern District of California, and indexed under 19-cv-01038, is on behalf of a class consisting of all persons and entities who purchased or otherwise acquired Heron securities between October 31, 2018 and April 30, 2019, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations ...
Jun 17, 2019 05:10 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APYX, NOK, HRTX and TUSK
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jun 14, 2019 12:36 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Heron Therapeutics, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 5, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ: 
Jun 14, 2019 11:44 am ET
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit...
Jun 14, 2019 11:00 am ET
Community Health Systems, Inc. (CYH) & Heron Therapeutics, Inc. (HRTX) - Bronstein, Gewirtz & Grossman, LLC Class Action Update
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 13, 2019 02:18 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Heron Therapeutics, Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming August 5, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ: HRTX) securities between October 31, 2018 and Apr
Jun 12, 2019 12:29 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Heron Therapeutics, Inc. (“Heron”) or the (“Company”) (NASDAQ:HRTX) of the August 5, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Jun 12, 2019 08:46 am ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc. (“Heron” or “the Company”) (NASDAQ: HRTX) for violations of §§10(b) and 20(a) of the Securities...
Jun 10, 2019 12:12 pm ET
HERON THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for Southern Dist
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that acquired Heron Therapeutics,...
Jun 07, 2019 01:27 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Heron Therapeutics, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ:
Jun 07, 2019 08:12 am ET
Robbins Arroyo LLP: Heron Therapeutics, Inc. (HRTX) Misled Shareholders According to a Recently Filed Lawsuit
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Heron Therapeutics, Inc. (NASDAQ: HRTX) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between October 31, 2018 and April 30, 2019. Heron Therapeutics is a biotechnology company tha
Jun 06, 2019 02:23 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Heron Therapeutics, Inc. Investors (HRTX)
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ: HRTX) securities between October 31, 2018 and April 30, 2019, inclusive (the “Class Period”). Heron Therapeutics investors
Jun 06, 2019 09:33 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc. (“Heron” or “the Company”) (NASDAQ: HRTX) for violations of §§10(b) and 20(a) of the Securities...
Jun 05, 2019 05:00 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Heron Therapeutics, Inc. Investors (HRTX)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ: HRTX) investors concerning the Company and its officers’ possible violations of federal securities laws.
Jun 05, 2019 03:55 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Heron Therapeutics, Inc. Investors (HRTX)
Law Offices of Howard G. Smith announces an investigation on behalf of Heron Therapeutics, Inc. (“Heron Therapeutics” or the “Company”) (NASDAQ: HRTX) investors concerning the Company and its officers’ possible violations of federal securities laws.
Jun 05, 2019 02:55 pm ET
HRTX REMINDER: ROSEN, A TOP RANKED LAW FIRM, Reminds Heron Therapeutics, Inc. Investors of Important Deadline in the Securities Class Action; Encourages Investors with Losses in Excess of $100K to Con
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive (the “Class Period”) of the important August 5, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Heron investors under the federal securities laws.
Jun 05, 2019 11:00 am ET
Heron Therapeutics, Inc. (HRTX) - Bronstein, Gewirtz & Grossman, LLC Announces Class Action and Lead Plaintiff Deadline: August 5, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Heron Therapeutics, Inc. (“Heron” or the “Company”) (NASDAQ: HRTX) and certain of its officers, on behalf of...
Jun 05, 2019 08:00 am ET
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact t
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc. (“Heron” or “the Company”) (NASDAQ:
Jun 05, 2019 06:11 am ET
CLASS ACTION UPDATE for PSMT and HRTX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jun 04, 2019 05:00 pm ET
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Heron Therapeutics, Inc. (NASDAQ: HRTX) and Encourages Heron Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Heron Therapeutics, Inc....
Jun 04, 2019 12:25 pm ET
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Heron Therapeutics, Inc.
Federman & Sherwood announces that on June 3, 2019, a class action lawsuit was filed in the United States District Court for the Southern District of California against Heron Therapeutics, Inc. (NASDAQ: HRTX). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is Octobe
Jun 04, 2019 09:46 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc. (“Heron” or “the Company”) (NASDAQ:
Jun 04, 2019 07:16 am ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Heron investors under the federal securities laws.
Jun 04, 2019 05:53 am ET
Pomerantz Law Firm Announces the Filing of a Class Action against Heron Therapeutics, Inc. and Certain Officers – HRTX
Pomerantz LLP announces that a class action lawsuit has been filed against Heron Therapeutics, Inc. (“Heron” or the “Company”) (NASDAQ: HRTX) and certain of its officers.   The class action, filed in United States District Court, for the Southern...
May 21, 2019 05:13 am ET
Heron Therapeutics Announces Publication of Results from Phase 3 EPOCH 1 Study of HTX-011 in Patients Undergoing Bunionectomy
SAN DIEGO, May 21, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the results from the pivotal Phase 3 EPOCH 1 bunionectomy study of the investigational agent HTX-011 have been published online by the Regional Anesthesia & Pain Medicine (RAPM) journal. The article, entitled "HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in bunionectomy: phase ...
May 14, 2019 11:36 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Heron Therapeutics, Inc. - HRTX
Pomerantz LLP is investigating claims on behalf of investors of Heron Therapeutics, Inc. (“Heron” or the “Company”) (NASDAQ: HRTX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
May 14, 2019 04:30 am ET
Heron Therapeutics Presents New Results from Real-world Study Showing 95% of Postoperative Patients Remain Opioid-Free when HTX-011 Is Given with an Over-the-Counter Analgesic Regimen
SAN DIEGO, May 14, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced results of a multi-center postoperative pain management study in 93 patients that provides real-world evidence of opioid-free recovery in patients undergoing outpatient inguinal hernia repair surgery who received the investigational agent, HTX-011, together with a scheduled background regimen of generic over-the-count...
May 09, 2019 04:30 am ET
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress
SAN DIEGO, May 9, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three months ended March 31, 2019 and highlighted recent corporate progress....
May 08, 2019 12:05 pm ET
Heron Therapeutics to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
SAN DIEGO, May 8, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, at 11:35 a.m. PDT at the Encore Hotel in Las Vegas, NV....
May 07, 2019 12:05 pm ET
Heron Therapeutics Partners with the National Academy of Medicine to Counter the Opioid Epidemic in the United States
SAN DIEGO, May 7, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced they joined the National Academy of Medicine's (NAM) Action Collaborative on Countering the U.S. Opioid Epidemic (Action Collaborative). ...
May 02, 2019 11:00 am ET
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Heron Therapeutics, Inc. (HRTX)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Heron Therapeutics, Inc. (“Heron” or the “Company”) (NASDAQ: HRTX). Such investors are encouraged to obtain additional...
May 01, 2019 05:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Heron Therapeutics, Inc. - HRTX
NEW YORK, May 1, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Heron Therapeutics, Inc. ("Heron" or the "Company") (NASDAQ: HRTX).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
May 01, 2019 05:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Heron Therapeutics, Inc. - HRTX
NEW YORK, May 1, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Heron Therapeutics, Inc. ("Heron" or the "Company") (NASDAQ: HRTX).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
May 01, 2019 04:00 am ET
Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain
SAN DIEGO, May 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on April 30, 2019 regarding its New Drug Application (NDA) for HTX-011 for the management of postoperative pain. ...
Apr 01, 2019 04:30 am ET
Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pain Management
SAN DIEGO, April 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the Marketing Authorisation Application (MAA) for its investigational agent, HTX-011, for postoperative pain, was validated by the European Medicines Agency (EMA). Validation of the MAA confirms that the submission is complete and starts the EMA's Centralised Procedure. The EMA granted eligibility to the Central...
Mar 11, 2019 04:30 am ET
77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study in Bunionectomy
SAN DIEGO, March 11, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced results of a multi-center postoperative pain management study in which 31 patients undergoing bunionectomy surgery received the investigational agent, HTX-011, together with a regimen of generic over-the-counter (OTC) oral analgesics (acetaminophen and ibuprofen). Designed as a follow-up to the Phase 3 study in buni...
Mar 05, 2019 02:25 am ET
Report: Exploring Fundamental Drivers Behind Caesars Entertainment, Party City Holdco, Rowan Companies, TiVo, Heron Therapeutics, and Cimarex Energy — New Horizons, Emerging Trends, and Upcoming Devel
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Caesars Entertainment Corporation (NASDAQ:CZR), Party City Holdco Inc....
Mar 04, 2019 10:05 am ET
Heron Therapeutics to Present at the 39th Annual Cowen Healthcare Conference
SAN DIEGO, March 4, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 39th Annual Cowen Healthcare Conference on Monday, March 11, 2019, at 2:10 p.m. EST at The Boston Marriott Copley Place....
Feb 26, 2019 10:05 am ET
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for IV Push
SAN DIEGO, Feb. 26, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved Heron's supplemental New Drug Application (sNDA) for CINVANTI (aprepitant) injectable emulsion, for intravenous (IV) use. The sNDA requested FDA approval to expand the administration of CINVANTI beyond the already approved administration method (a 30-minut...
Feb 22, 2019 02:30 am ET
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Recent Corporate Progress
SAN DIEGO, Feb. 22, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and twelve months ended December 31, 2018 and highlighted recent corporate progress....
Feb 20, 2019 10:05 am ET
Heron Therapeutics to Present at the 8th Annual Leerink Partners Global Healthcare Conference
SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the 8th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019, at 1:00 p.m. EST at the Lotte New York Palace Hotel. ...
Feb 05, 2019 10:30 am ET
Heron Therapeutics Announces Retirement of Robert Rosen as President
SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Robert Rosen, President, will be retiring. Mr. Rosen's responsibilities will be transitioned to Barry Quart, Pharm.D., Chief Executive Officer of Heron, who will take on the additional role of President....
Jan 30, 2019 02:35 am ET
New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Heron Therapeutics, Inc. (NASDAQ:HRTX), IDACORP, Inc. (NYSE:IDA), Star...
Jan 07, 2019 02:30 am ET
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
SAN DIEGO, Jan. 7, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlighted progress in its pain management and chemotherapy-induced nausea and vomiting (CINV) franchises....
Jan 03, 2019 02:30 am ET
90% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study
SAN DIEGO, Jan. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced results of a multi-center postoperative pain management study in which 63 patients undergoing hernia repair surgery received the investigational agent, HTX-011, together with a regimen of generic over-the-counter (OTC) oral analgesics (acetaminophen and ibuprofen). Designed as a follow-up to the Phase 3 study in herni...
Dec 31, 2018 10:05 am ET
Heron Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019, at 5:00 p.m. PST at the Westin St. Francis hotel in San Francisco, CA....
Dec 31, 2018 02:30 am ET
FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management
SAN DIEGO, Dec. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for Heron's investigational agent, HTX-011, and has granted it a Priority Review designation. HTX-011 is a long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the ant...
Nov 27, 2018 02:50 am ET
Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aclaris Therapeutics, Inc. (NASDAQ:ACRS), Extreme Networks, Inc....
Nov 20, 2018 10:05 am ET
Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference
SAN DIEGO, Nov. 20, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018, at 10:15 a.m. EST at the Boston Harbor Hotel. ...
Nov 12, 2018 10:01 am ET
U.S. Surgeon General Jerome Adams Discusses Opioid Alternatives and the Importance of Partnerships at Heron Therapeutics
SAN DIEGO, Nov. 12, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today hosted a fireside chat with the U.S. Surgeon General, Vice Admiral Jerome M. Adams, M.D., M.P.H. It was a familiar venue for Dr. Adams, as he continues to visit communities across the country and advocate for forming non-traditional partnerships with businesses, faith-based communities and law enforcement agencies to tackle th...
Nov 07, 2018 10:05 am ET
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress
SAN DIEGO, Nov. 7, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and nine months ended September 30, 2018 and highlighted recent corporate progress....
Oct 31, 2018 12:01 pm ET
Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management
SAN DIEGO, Oct. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-011. HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative...
Oct 12, 2018 03:40 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Cloud Peak Energy, Ralph Lauren, CytomX Therapeutics, Extreme Networks, Heron Therapeutics, and Alteryx — New Research Emphasizes Ec
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cloud Peak Energy Inc (NYSE:CLD), Ralph Lauren Corporation (NYSE:RL),...
Sep 24, 2018 12:05 pm ET
Heron Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
SAN DIEGO, Sept. 24, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018, at 2:20 p.m. EDT at the Intercontinental New York Barclay Hotel. ...
Aug 13, 2018 04:00 am ET
New Research Coverage Highlights East West, Heron Therapeutics, Invacare, CNO Financial Group, Fortinet, and Realogy — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of East West Bancorp, Inc. (NASDAQ:EWBC), Heron Therapeutics, Inc....
Aug 08, 2018 04:30 am ET
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress
SAN DIEGO, Aug. 8, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and six months ended June 30, 2018 and highlighted recent corporate progress....
Jun 25, 2018 06:01 pm ET
Heron Therapeutics Announces Pricing of Public Offering of Common Stock
Heron Therapeutics, Inc. (“Heron”) (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the pricing of an underwritten public offering of approximately $200 million of shares of its common stock. In addition, Heron has granted the underwriter of the offering a 30-day option to purchase up to an additional approximately $30 million of shares of its common stock. The offering is expected t
Jun 25, 2018 12:01 pm ET
Heron Therapeutics Announces Public Offering of Common Stock
Heron Therapeutics, Inc. (“Heron”) (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced an underwritten public offering of approximately $200 million of shares of its common stock. In addition, Heron has granted the underwriter of the offering a 30-day option to purchase up to an additional approximately $30 million of shares of its common stock. All of the shares of common stock in the
Jun 21, 2018 04:05 am ET
HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that HTX-011 for postoperative pain management has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammator
Jun 21, 2018 04:00 am ET
Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced positive topline results from two completed Phase 2b studies of HTX-011: Study 209 (local administration in total knee arthroplasty) and Study 211 (instillation or pectoral pocket nerve block in breast augmentation). HTX-011 achieved the primary endpoints in both studies.
May 29, 2018 12:05 pm ET
Heron Therapeutics to Present at the Jefferies 2018 Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018, at 2:00 p.m. EDT at the Grand Hyatt New York Hotel.
May 14, 2018 04:10 am ET
Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Advaxis, Inc. (NASDAQ:ADXS), e.l.f. Beauty Inc. (NYSE:ELF), Heron...
May 10, 2018 04:30 am ET
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three months ended March 31, 2018 and highlighted recent corporate progress.
May 09, 2018 12:05 pm ET
Heron Therapeutics to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Bank of America Merrill Lynch 2018 Healthcare Conference on Wednesday, May 16, 2018, at 1:00 p.m. PDT at the Encore Hotel in Las Vegas, NV.
Mar 28, 2018 04:53 pm ET
Heron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the pricing of an underwritten public offering of 6 million shares of its common stock, offered at a price of $26.00 per share. Heron Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock on the same terms and conditions. All shares of comm
Mar 28, 2018 12:14 pm ET
Heron Therapeutics Announces Proposed Public Offering of Common Stock
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Heron Therapeutics, Inc. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be co
Mar 21, 2018 12:05 pm ET
Heron Therapeutics to Present at the 17th Annual Needham Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018, at 12:45 p.m. EDT at the Westin Grand Central Hotel, New York.
Mar 19, 2018 04:00 am ET
Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials of HTX-011 in Bunionectomy and Hernia Repair
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced positive topline results from its completed Phase 3 studies of the investigational agent HTX-011 in subjects undergoing bunionectomy (Study 301/EPOCH1) and hernia repair (Study 302/EPOCH2). HTX-011 achieved all primary and key secondary endpoints in both Phase 3 trials, demonstrating statistically signif
Mar 06, 2018 11:05 am ET
Heron Therapeutics to Present at the 38th Annual Cowen Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 38th Annual Cowen Healthcare Conference on Monday, March 12, 2018, at 3:30 p.m. EST at the Boston Marriott Copley Place.
Feb 27, 2018 11:15 am ET
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and twelve months ended December 31, 2017 and highlighted recent corporate progress.
Feb 12, 2018 11:05 am ET
Heron Therapeutics to Present at the 7th Annual Leerink Partners Global Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will participate in a fireside chat at the 7th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 14, 2018, at 1:00 p.m. EST at the Lotte New York Palace Hotel.
Feb 09, 2018 02:45 am ET
Research Report Identifies Hill-Rom, Quantum, Heron Therapeutics, Dillard's, LightPath Technologies, and Adesto Technologies with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hill-Rom Holdings Inc (NYSE:HRC), Quantum Corporation...
Jan 08, 2018 03:30 am ET
Heron Therapeutics Highlights Progress in CINV and Pain Management Franchises
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, today highlighted progress in the Company’s pain management and CINV franchises.
Jan 02, 2018 11:05 am ET
Heron Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018, at 5:00 p.m. PST at the Westin St. Francis hotel in San Francisco, CA.
Dec 05, 2017 04:00 am ET
Heron Therapeutics Announces Pricing of Public Offering of Common Stock
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the pricing of an underwritten public offering of $150 million of shares of its common stock. Heron Therapeutics, Inc. has granted the underwriter a 30-day option to purchase up to an additional $22.5 million of shares of common stock. The offering is expected to close on or about December 7, 2017, subje
Dec 04, 2017 11:01 am ET
Heron Therapeutics Announces Public Offering of Common Stock
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced an underwritten public offering of its common stock. The closing price of Heron Therapeutics, Inc.’s common stock on December 1, 2017 was $17.25 per share.
Nov 20, 2017 03:10 am ET
Recent Analysis Shows Premier, Quantum, Heron Therapeutics, Dillard's, LightPath Technologies, and Ichor Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Premier, Inc. (NASDAQ:PINC), Quantum Corporation (NYSE:QTM),...
Nov 09, 2017 11:05 am ET
Heron Therapeutics Announces U.S. FDA Approval of CINVANTI™ (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)
Heron Therapeutics, Inc. (Nasdaq: HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved CINVANTI™ (aprepitant) injectable emulsion, for intravenous infusion. CINVANTI is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of acute and del
Nov 08, 2017 11:05 am ET
Heron Therapeutics to Present at the Jefferies London Healthcare Conference
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Jefferies London Healthcare Conference on Thursday, November 16, 2017, at 4:00 p.m. GMT (11:00 a.m. EST).
Nov 06, 2017 03:30 am ET
Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress
Heron Therapeutics, Inc. (Nasdaq:HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and nine months ended September 30, 2017 and highlighted recent corporate progress.
Oct 26, 2017 04:30 am ET
Heron Therapeutics Granted FDA Fast Track Designation for HTX-011 to Reduce Postoperative Pain and the Need for Opioid Analgesics for 72 Hours
Heron Therapeutics, Inc. (Nasdaq: HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel best-in-class treatments to address some of the most important unmet patient needs, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s investigational agent, HTX-011, for local administration into the surgical site to reduce postoperative pain and the need for opioid analgesics for 72 hours. Fast Track designation is a process designed to faci
Oct 20, 2017 04:10 am ET
Oct 21, 2016 08:00 am ET
InvestorsObserver releases covered-call reports for Inovio Pharmaceuticals, Varian Medical Systems, Heron Therapeutics, Chipotle Mexican Grill and Wynn Resorts
CHICAGO, Oct. 21, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CMG, HRTX, INO, VAR, and WYNN....